Teva receives CRL for reformulated schizophrenia drug developed with French biotech
Though Teva Pharmaceuticals is largely known for its biosimilars business, it still engages in the occasional, traditional research agreements with smaller biotechs. But one such deal ran into a brick wall at the FDA late Tuesday.
Teva and its partners at the French biotech MedinCell received a complete response letter for their subcutaneous schizophrenia treatment, the companies announced Tuesday afternoon. The pair did not provide a reason as to why regulators issued the CRL, but MedinCell noted in a statement that Teva would be responsible for resolving any concerns.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
